MIFH
HEPA

Migdal Insurance & Financial Holdings’s Hepion Pharmaceuticals HEPA Stock Holding History

Migdal Insurance & Financial Holdings’s Portfolio HEPA Stock Details HEPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2
Closed -$2K – 646
2021
Q4 		$2K Sell
2
-1
-33% -$1.37K ﹤0.01% 666
2021
Q3 		$4K Buy
+3
New +$4.8K ﹤0.01% 640

Other funds holding HEPA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
ML
McAdam LLC Philadelphia, Pennsylvania $2.59B AUM 21.24% 1-Year Est. Return

Migdal Insurance & Financial Holdings's HEPA Position: Q1 2022 in Review

Migdal Insurance & Financial Holdings sold out of Hepion Pharmaceuticals (HEPA) in Q1 2022, closing a stake of 2 shares — an estimated $2K sold.

Migdal Insurance & Financial Holdings first reported a position in HEPA in Q3 2021 and held it in 2 quarters. The position peaked at $4K in Q3 2021. 31 funds tracked by Wall St. Rank hold HEPA as of Q1 2022.

  • Migdal Insurance & Financial Holdings reported no remaining Hepion Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Migdal Insurance & Financial Holdings sold 2 Hepion Pharmaceuticals shares in Q1 2022, an estimated $2K.
  • Migdal Insurance & Financial Holdings first reported a position in Hepion Pharmaceuticals in Q3 2021 and held it in 2 quarters.
  • Migdal Insurance & Financial Holdings's Hepion Pharmaceuticals position peaked at $4K in Q3 2021.
  • 31 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q1 2022.

Based on Migdal Insurance & Financial Holdings's 13F filing for Q1 2022, filed 2 May 2022.